ClinicalTrials.gg

Program

HT-102

A development code. Also written as “HT-101 + HT-102”.

Its studies are mostly in Hepatitis B, Chronic, led by Suzhou HepaThera Biotech.

Furthest: phase 2, since Nov 17, 20253 company-led studies, 2 open or runningNext primary completion: Feb 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Suzhou HepaThera Biotech32 open or runningphase 2since Nov 17, 2025Dec 9, 2024Feb 2027phase 2 · NCT07245953

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2024First study: phase 1 study in Hepatitis B, ChronicFirst studyNCT06744686 · 56 enrolled · China
  2. Nov 17, 2025Phase 2 study in Hepatitis B, ChronicPhase 2 reachedNCT07245953 · 60 enrolled · China
  3. Oct 29, 2026Phase 2 study in Hepatitis B, ChronicNCT07917910 · 120 planned

Ahead

  1. Feb 2027Primary completion: phase 2 study in Hepatitis B, ChronicNCT07245953
  2. Oct 30, 2028Primary completion: phase 2 study in Hepatitis B, ChronicNCT07917910

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07917910Hepatitis B, Chronic2Not yet recruitingOct 30, 2028120
NCT07245953Hepatitis B, Chronic · China2Active, not recruitingFeb 202760
NCT06744686Hepatitis B, Chronic · China1CompletedMar 12, 202456

How it is read

Names in the registry

  • “HT-102”, 3 entries
  • “HT-101 + HT-102”, 1 entry

Codes read as this program: HT102.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.